Andera Partners
AVLN icon

Andera Partners’s Avalyn Pharma AVLN Stock Holding History

Andera Partners’s Portfolio AVLN Stock Details AVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$26.5M Hold
929,824
– – 15.08% 3
2026
Q2 		$30.6M Buy
+929,824
New +$26.8M 14.82% 3

Other funds holding AVLN

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Lewis Asset Management
Lewis Asset Management Lafayette, California $294M AUM 25.62% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
STRS Ohio
STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Manchester Capital Management
Manchester Capital Management Manchester, Vermont $736M AUM 20.83% 1-Year Est. Return

Andera Partners's AVLN Position: Q3 2026 in Review

Andera Partners held its Avalyn Pharma (AVLN) position steady in Q3 2026 at 929,824 shares worth $26.5M. The position accounts for 15.08% of the portfolio, ranked #3.

Andera Partners first reported a position in AVLN in Q2 2026 and has held it in 2 quarters since. The position peaked at $30.6M in Q2 2026. 23 funds tracked by Wall St. Rank hold AVLN as of Q3 2026.

  • Andera Partners held 929,824 shares of Avalyn Pharma worth $26.5M as of Q3 2026.
  • Andera Partners left its Avalyn Pharma share count unchanged in Q3 2026.
  • Avalyn Pharma made up 15.08% of Andera Partners's portfolio in Q3 2026, its #3 holding.
  • Andera Partners first reported a position in Avalyn Pharma in Q2 2026 and has held it in 2 quarters since.
  • Andera Partners's Avalyn Pharma position peaked at $30.6M in Q2 2026.
  • 23 funds tracked by Wall St. Rank held Avalyn Pharma as of Q3 2026.

Based on Andera Partners's 13F filing for Q3 2026, filed 16 Oct 2026.